DexCom Inc (BSP:D1EX34)
R$ 9.65 0 (0%) Market Cap: 188.46 Bil Enterprise Value: 189.06 Bil PE Ratio: 48.19 PB Ratio: 15.88 GF Score: 74/100

Dexcom Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 10, 2022 / 03:30PM GMT
Release Date Price: R$12.43 (-8.89%)
Robert Justin Marcus
JPMorgan Chase & Co, Research Division - Analyst

Morning, everyone. Happy to introduce our next company. We have DexCom's CEO, Kevin Sayer, joining us now. And following up in the Q&A session, we'll also have Jereme Sylvain, the CFO of DexCom.

(Operator Instructions)

But for now, Kevin, I'm going to turn it over to you and join you in a little bit.

Kevin Ronald Sayer
DexCom, Inc. - Executive Chairman, CEO & President

Well, Robbie, thanks for having us again this year. We're going to start on Slide 3, and it's a great day for us. I want to start by emphasizing that DexCom still has, and we have tremendous opportunities ahead of us. I've been doing this for a long time with respect to diabetes and the story never changes.

Diabetes continues to grow, be a big problem and it never slows down. And consistently, DexCom has provided the best outcomes and solution across all diabetes. We have a lot of runway left in our U.S. market. While we've achieved a lot of penetration here, there's still plenty of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot